US Edition
Stakeholder Considerations for IPAY 2028 Guidance
Summary by avalerehealth.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Stakeholder Considerations for IPAY 2028 Guidance
On May 12, the Centers for Medicare & Medicaid Services (CMS) released draft guidance detailing the selection and negotiation processes for Medicare Part B and Part D drugs for Initial Price Applicability Year (IPAY) 2028. This guidance builds upon the framework established in previous years and introduces several key changes, including the eligibility of Part B drugs for selection. Key Changes for IPAY 2028 Drug Selection and Eligibility: …
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
